The latest price target for Spyre Therapeutics (NASDAQ:SYRE) was reported by Jones Trading on December 11, 2024. The analyst firm set a price target for $0.00 expecting SYRE to fall to within 12 months (a possible -100.00% downside). 10 analyst firms have reported ratings in the last year.

The latest analyst rating for Spyre Therapeutics (NASDAQ:SYRE) was provided by Jones Trading, and Spyre Therapeutics initiated their hold rating.

The last upgrade for Spyre Therapeutics Inc happened on March 1, 2024 when Wells Fargo raised their price target to $35. Wells Fargo previously had an equal-weight for Spyre Therapeutics Inc.

There is no last downgrade for Spyre Therapeutics.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Spyre Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Spyre Therapeutics was filed on December 11, 2024 so you should expect the next rating to be made available sometime around December 11, 2025.

While ratings are subjective and will change, the latest Spyre Therapeutics (SYRE) rating was a initiated with a price target of $0.00 to $0.00. The current price Spyre Therapeutics (SYRE) is trading at is $24.42, which is out of the analyst’s predicted range.